GSK: Jemperli continues to show ‘unprecedented results, in dMMR rectal cancer

GSK announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli or dostarlimab-gxly as a first-line treatment-as an alternative to surgery-for mismatch repair deficient dMMR locally advanced rectal cancer. The trial showed an unprecedented 100% clinical complete response rate cCR in 42 patients who completed treatment with dostarlimab-gxly, defined as complete pathologic response or no evidence of tumors as assessed by magnetic resonance imaging, endoscopy and digital rectal exam. In the first 24 patients evaluated, a sustained clinical complete response with a median follow-up of 26.3 months was observed. These late-breaking data are being presented today at the 2024 American Society of Clinical Oncology ASCO Annual Meeting in Chicago, IL as a rapid oral presentation . The latest research presented today from the phase II trial builds on the findings initially presented in a late-breaking presentation at the 2022 ASCO Annual Meeting with simultaneous publication in The New England Journal of Medicine.1